Phase I Study of Pomalidomide, Bortezomib, and Dexamethasone (PVD) as First-Line Treatment of AL Amyloidosis or Light Chain Deposition Disease
This phase I trial studies the side effects and best dose of pomalidomide and bortezomib
when given together with dexamethasone in treating patients with amyloid light-chain
amyloidosis or light chain deposition disease. Biological therapies, such as pomalidomide,
may stimulate the immune system in different ways and stop abnormal cells from growing.
Bortezomib may stop the growth of abnormal cells by blocking some of the enzymes needed for
cell growth. Giving pomalidomide and bortezomib together with dexamethasone may be an
effective treatment for amyloid light-chain amyloidosis or light chain deposition disease
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society